Editing Tacrolimus (section)

===Skin===
{{See also|Eczema#Medications|l1=Medications used in treatment of eczema}}
[[File:Protopic.JPG|thumb|Tacrolimus 0.1% Ointment]]

As an [[ointment]], tacrolimus is used in the treatment of [[dermatitis]] (eczema), in particular [[atopic dermatitis]], if topical corticosteroids and moisturisers fail in helping.<ref>{{cite journal |vauthors = Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM |title = Topical tacrolimus for atopic dermatitis |journal = The Cochrane Database of Systematic Reviews |volume = 2015 |issue = 7 |pages = CD009864 |date = July 2015 |pmid = 26132597 |pmc = 6461158 |doi = 10.1002/14651858.CD009864.pub2 }}</ref><ref name="Cancer risk with topical calcineuri">{{cite journal |vauthors = Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, MacDonald M, Wen A, Steen J, Levine M, Pyne L, Schneider L, Chu DK |title = Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis |journal = The Lancet. Child & Adolescent Health |volume = 7 |issue = 1 |pages = 13–25 |date = January 2023 |pmid = 36370744 |doi = 10.1016/S2352-4642(22)00283-8 |s2cid = 253470127 }}</ref> It suppresses inflammation in a similar way to [[steroid]]s, and is equally as effective as a mid-potency steroid.  An important advantage of tacrolimus is that, unlike steroids, it does not cause skin thinning ([[atrophy]]), or other steroid related side effects.<ref name="AC-Protopic" /><ref name="Cancer risk with topical calcineuri"/>

It is applied on the active lesions until they heal off, but may also be used continuously in low doses (twice a week), and applied to the thinner skin over the face and eyelids.{{Citation needed|date=December 2008}} Clinical trials of up to one year have been conducted. Recently it has also been used to treat segmental [[vitiligo]] in children, especially in areas on the face.<ref>{{cite journal |vauthors = Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, Chamlin SL, Paller AS |title = Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases |journal = Journal of the American Academy of Dermatology |volume = 51 |issue = 5 |pages = 760–766 |date = November 2004 |pmid = 15523355 |doi = 10.1016/j.jaad.2004.05.036 }}</ref>